BPC-157 vs Gonadorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →Gonadorelin
Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH). It stimulates the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), supporting natural hormone production.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 | Gonadorelin |
|---|---|---|
| Mechanism | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. | Binds to GnRH receptors in the pituitary gland, triggering pulsatile release of LH and FSH. This stimulates testicular or ovarian function and natural sex hormone production. |
| Typical Dosage | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. | Men: 100-200mcg subcutaneously 2-3 times daily. Women (fertility): Per clinical protocol. HRT support: Often combined with other therapies. |
| Administration | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. | Subcutaneous injection. Pulsatile administration mimics natural GnRH release patterns. Often used during or after testosterone therapy. |
| Side Effects | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. | Headache, flushing, injection site reactions. In women may cause ovarian hyperstimulation. Generally well-tolerated. |
| Best For |